These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28621575)

  • 1. Analysis of radio-sensitization patents in China from 2006 to 2015.
    He G; Di X; Sun X; Yan J; Zhang S
    Expert Opin Ther Pat; 2017 Oct; 27(10):1159-1172. PubMed ID: 28621575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on anti-allergic patents granted in China: 2009 - 2011.
    Zhang S; Zeng X; He S
    Expert Opin Ther Pat; 2012 Jul; 22(7):715-34. PubMed ID: 22702413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of patents on anti-allergic therapies issued in China from 1988 to 2008.
    Zhang S; Zeng X; Wei J; Li S; He S
    Expert Opin Ther Pat; 2010 Jun; 20(6):727-37. PubMed ID: 20476846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of trends and opportunities of anti-allergy patents in China from 1998 to 2008.
    Zhang S; Zeng X; Wei J; Li S; He S
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):130-7. PubMed ID: 20394584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.
    Xie H; Zhang H; Cao K; He P; Dai H; He S
    Expert Opin Ther Pat; 2016; 26(3):363-76. PubMed ID: 26742645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of patents on anti-rheumatoid arthritis therapies issued in China.
    Yuan HY; Zhang XL; Zhang XH; Meng L; Wei JF
    Expert Opin Ther Pat; 2015; 25(8):909-30. PubMed ID: 26066366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of anti-lung cancer drug patents applications in China from 2003 to 2012.
    Chen DM; Mao KY; Yang L; Jiang HB
    Recent Pat Anticancer Drug Discov; 2014 May; 9(2):221-40. PubMed ID: 24171822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of patents on anti-gout therapies issued in China.
    Yuan HY; Zhang XH; Zhang XL; Wei JF; Meng L
    Expert Opin Ther Pat; 2014 May; 24(5):555-72. PubMed ID: 24605811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of antibiotic patents issued in China from 1992 to 2011.
    Xie H; Zhang H; Zhang S; He S
    Expert Opin Ther Pat; 2012 Oct; 22(10):1205-32. PubMed ID: 22957903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a peptide enhancing the ability of radiation therapy to kill cancer cells: a patent evaluation of WO2012016918.
    Xu J; Wei Q
    Expert Opin Ther Pat; 2012 Dec; 22(12):1485-7. PubMed ID: 22871163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
    Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cluster analysis on authorized patents of compound traditional Chinese medicines with different efficacy in 2010].
    Yang X; Xiao S; Guo Z
    Zhongguo Zhong Yao Za Zhi; 2012 Aug; 37(16):2478-82. PubMed ID: 23234154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analyses on positive influence of harmonous development of traditional Chinese medicine compounds' researchs and patent protection].
    Yang X; Xiao S; Guo Z; Wang Z; You Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):9-12. PubMed ID: 22741453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors as antitumor agents: a patent update (2013-2015).
    Yuan Z; Chen J; Li W; Li D; Chen C; Gao C; Jiang Y
    Expert Opin Ther Pat; 2017 Mar; 27(3):363-382. PubMed ID: 27841036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China.
    Xu W; Towers AD; Li P; Collet JP
    Eur J Cancer Care (Engl); 2006 Sep; 15(4):397-403. PubMed ID: 16968323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Concept of therapeutic ratio by combination of radiotherapy and chemotherapy].
    Tanaka Y
    Gan No Rinsho; 1983 Oct; 29(13):1579-83. PubMed ID: 6668667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CUPID: a protocol of a randomised controlled trial to identify characteristics of similar Chinese patent medicines.
    Cao H; Zhai J; Li N; Cao H; Lei X; Mu W; Liu Z; Wang H; Shang H
    BMJ Open; 2014 Nov; 4(11):e006753. PubMed ID: 25431225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor patents (2010 - present).
    Metcalf R; Scott LM; Daniel KG; Dou QP
    Expert Opin Ther Pat; 2014 Apr; 24(4):369-82. PubMed ID: 24450483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer.
    Qi F; Zhao L; Zhou A; Zhang B; Li A; Wang Z; Han J
    Biosci Trends; 2015 Feb; 9(1):16-34. PubMed ID: 25787906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
    Bischoff P; Altmeyer A; Dumont F
    Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.